Table of Contents
Understanding the mechanisms of action of FDA-approved therapies is essential for healthcare professionals, researchers, and students. These therapies include a wide range of drugs and biological agents designed to target specific pathways in the body to treat various diseases.
Overview of FDA-Approved Therapies
FDA approval signifies that a therapy has been rigorously tested for safety and efficacy. These therapies can be categorized into small molecule drugs, biologics, gene therapies, and cell-based treatments. Each category functions through distinct mechanisms to achieve therapeutic effects.
Mechanisms of Action of Key Therapies
1. Enzyme Inhibition
Many drugs work by inhibiting enzymes that are involved in disease pathways. For example, ACE inhibitors block the angiotensin-converting enzyme, reducing blood pressure in hypertensive patients. Similarly, HIV protease inhibitors prevent viral maturation by inhibiting viral enzymes.
2. Receptor Modulation
Therapies targeting receptors can either activate or block them. Beta-blockers inhibit beta-adrenergic receptors to decrease heart rate and blood pressure. Conversely, selective serotonin reuptake inhibitors (SSRIs) enhance serotonin signaling by blocking reuptake in the brain, alleviating depression.
3. Immune Modulation
Biologics often modulate the immune system. Monoclonal antibodies like trastuzumab target specific proteins on cancer cells, marking them for destruction. Immune checkpoint inhibitors, such as pembrolizumab, block inhibitory pathways in T-cells to enhance immune responses against tumors.
4. Gene Expression Alteration
Gene therapies introduce, remove, or alter genetic material within a patient’s cells. For example, Luxturna delivers a correct copy of a mutated gene to restore vision in inherited retinal diseases. Similarly, antisense oligonucleotides can modify splicing or suppress harmful gene expression.
Examples of FDA-Approved Therapies and Their Actions
1. Pembrolizumab (Keytruda)
Pembrolizumab is a monoclonal antibody that inhibits PD-1, a receptor on T-cells. This blockade enhances immune response against cancer cells, making it effective in various cancers such as melanoma and lung cancer.
2. Imatinib (Gleevec)
Imatinib inhibits the BCR-ABL tyrosine kinase, a fusion protein found in chronic myeloid leukemia. Its targeted inhibition prevents cancer cell proliferation.
3. Nusinersen (Spinraza)
Nusinersen is an antisense oligonucleotide that modifies splicing of the SMN2 gene, increasing production of functional SMN protein and treating spinal muscular atrophy.
Conclusion
The diverse mechanisms of action of FDA-approved therapies reflect the complexity of human diseases. Advances in understanding these mechanisms continue to drive the development of more targeted and effective treatments, improving patient outcomes worldwide.